These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19690066)

  • 1. A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy.
    Blümer RM; van der Valk M; Ackermans M; Endert E; Serlie MJ; Reiss P; Sauerwein HP
    Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1097-104. PubMed ID: 19690066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
    Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
    Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
    Blümer RM; van Vonderen MG; Sutinen J; Hassink E; Ackermans M; van Agtmael MA; Yki-Jarvinen H; Danner SA; Reiss P; Sauerwein HP
    AIDS; 2008 Jan; 22(2):227-36. PubMed ID: 18097225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
    Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
    Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
    Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S
    J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy.
    Sutinen J; Kannisto K; Korsheninnikova E; Fisher RM; Ehrenborg E; Nyman T; Virkamäki A; Funahashi T; Matsuzawa Y; Vidal H; Hamsten A; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E941-9. PubMed ID: 14749206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adipocyte-derived hormone levels in HIV lipodystrophy.
    Kosmiski L; Kuritzkes D; Lichtenstein K; Eckel R
    Antivir Ther; 2003 Feb; 8(1):9-15. PubMed ID: 12713059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients.
    van der Valk M; Allick G; Weverling GJ; Romijn JA; Ackermans MT; Lange JM; van Eck-Smit BL; van Kuijk C; Endert E; Sauerwein HP; Reiss P
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3554-60. PubMed ID: 15240645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).
    Slama L; Lanoy E; Valantin MA; Bastard JP; Chermak A; Boutekatjirt A; William-Faltaos D; Billaud E; Molina JM; Capeau J; Costagliola D; Rozenbaum W
    Antivir Ther; 2008; 13(1):67-76. PubMed ID: 18389900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
    Krag MB; Nielsen S; Guo Z; Pedersen SB; Schmitz O; Christiansen JS; Jørgensen JO
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):452-61. PubMed ID: 18331610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
    Kovacic JC; Martin A; Carey D; Wand H; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr A;
    Antivir Ther; 2005; 10(1):135-43. PubMed ID: 15751771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
    Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
    Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.
    Hadigan C; Yawetz S; Thomas A; Havers F; Sax PE; Grinspoon S
    Ann Intern Med; 2004 May; 140(10):786-94. PubMed ID: 15148065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.
    Mulligan K; Yang Y; Wininger DA; Koletar SL; Parker RA; Alston-Smith BL; Schouten JT; Fielding RA; Basar MT; Grinspoon S
    AIDS; 2007 Jan; 21(1):47-57. PubMed ID: 17148967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.
    Carr A; Workman C; Carey D; Rogers G; Martin A; Baker D; Wand H; Law M; Samaras K; Emery S; Cooper DA;
    Lancet; 2004 Feb; 363(9407):429-38. PubMed ID: 14962523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism.
    Samaras K; Wand H; Law M; Emery S; Cooper DA; Carr A
    Curr HIV Res; 2009 Jul; 7(4):454-61. PubMed ID: 19601783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome.
    Glintborg D; Frystyk J; Højlund K; Andersen KK; Henriksen JE; Hermann AP; Hagen C; Flyvbjerg A; Andersen M
    Clin Endocrinol (Oxf); 2008 Feb; 68(2):165-74. PubMed ID: 17803698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.
    Tomazic J; Karner P; Vidmar L; Maticic M; Sharma PM; Janez A
    Acta Dermatovenerol Alp Pannonica Adriat; 2005 Sep; 14(3):99-105. PubMed ID: 16200335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.